Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 82; no. 4; pp. 575 - 577
Main Authors Dougados, Maxime, Charles-Schoeman, Christina, Szekanecz, Zoltán, Giles, Jon T, Ytterberg, Steven R, Bhatt, Deepak L, Koch, Gary G, Vranic, Ivana, Wu, Joseph, Wang, Cunshan, Kwok, Kenneth, Menon, Sujatha, Connell, Carol A, Yndestad, Arne, Rivas, Jose L, Buch, Maya H
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group Ltd and European League Against Rheumatism 01.04.2023
Elsevier Limited
BMJ Publishing Group
Subjects
Antirheumatic Agents
Antirheumatic Agents - adverse effects
Arthritis, Rheumatoid
Arthritis, Rheumatoid - chemically induced
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - epidemiology
Cardiology
Cardiovascular disease
Cardiovascular Diseases
Cardiovascular Diseases - chemically induced
Clinical trials
Coronary vessels
Heart Disease Risk Factors
Humans
Incidence
Letter
Patients
Pyrroles - adverse effects
Rheumatoid arthritis
Risk Factors
Surveillance
Treatment Outcome
Vein & artery diseases
New York
United States > US
Antirheumatic Agents
Cardiovascular Diseases
Arthritis, Rheumatoid
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Correspondence-2
ObjectType-Letter to the Editor-1
ObjectType-Article-2
ObjectType-Correspondence-1
content type line 23
ISSN:0003-4967
1468-2060
1468-2060
DOI:10.1136/ard-2022-223406